IUBio Biosequences .. Software .. Molbio soft .. Network News .. FTP

ONCONASE (Ribonuclease) Variant Exhibits Anti-Viral Activity

Carmine M. Zingarino gn686 at cleveland.Freenet.Edu
Thu Jul 18 20:55:46 EST 1996


BW1289  JUL 18,1996      11:17  PACIFIC      14:17  EASTERN           
                                                                       
                                                                  
( BW)(ALFACELL)(ACEL) ALFACELL scientists report on characterization  
of a natural variant of ONCONASE; Data presented at 4th International
Ribonuclease Conference                                                
                                                                      
    Business Editors & Medical Writers                           
                                                          
    BLOOMFIELD, N.J.--(BUSINESS WIRE)--July 18, 1996--ALFACELL Corp.    
(OTCBB:ACEL) announced today that research results from ALFACELL as
well as a number of independent collaborators from the National  
Institutes of Health including the National Cancer Institute were     
presented at the 4th International Ribonucleases: Chemistry,           
Biology, Biotechnology conference, July 14-18, 1996 in Groningen,
Holland.                                                            
    The research presented included new pre-clinical findings on the
cytotoxicity and anti-viral activity of ONCONASE(R), as well as        
structure and function studies of ONCONASE and its natural variant.   
ONCONASE, a novel ribonuclease (RNase), is currently in Phase III       
clinical trials.                                                      
    The presentation "Anti-Tumor Ribonucleases, Characterization of    
a Natural Variant of ONCONASE" made by Dr. Wojciech Ardelt,       
ALFACELL's Director of Biochemistry, reported on the discovery and    
characterization including (structure and function studies) of       
ONCONASE and its natural variant.  The variant also exhibited          
anti-proliferative (inhibition of cancer growth) and cytotoxic (cancer
cell death) activity against human cancer cell lines such as     
submaxillary gland carcinoma and bladder carcinoma.       
    "The knowledge we have gained from these structure and function     
studies play a vital role in our genetic engineering program to    
develop the next generations of ONCONASE-based RNase products for
therapeutic applications,"  stated Dr. Ardelt.                        
    Developed by ALFACELL scientists, ONCONASE(R) is a structurally    
and functionally novel RNase protein used in the investigational 
treatment of patients with solid tumors, most of which are resistant
to other chemotherapeutic drugs.  ONCONASE, the only cytotoxic RNase
currently in clinical trials, has been used in the treatment of over   
350 patients with a variety of solid tumors and has demonstrated      
activity in multiple-drug resistant (MDR) tumor lines as well as in     
vivo activity in MDR tumor models.  MDR is thought to be responsible  
for approximately 90% of chemotherapy failures.  The company is        
currently conducting multi-center Phase III clinical trials in    
advanced pancreatic cancer patients as well as a                      
multi-center Phase II trial in malignant mesothelioma patients.      
    ALFACELL Corporation, a biopharmaceutical company located in       
Bloomfield, N.J. is engaged primarily in the research and             
development of novel ribonuclease enzymes for various therapeutic
applications.  The company's common stock is traded in the
over-the-counter market under the symbol "ACEL".                        
                                                                   
    --30--eb/bk/ny*                                              
                                                                      
    CONTACT: Donna Brasko                                              
             Director, Corporate Communications                  
             201/748-8082                                           
                                                                    
    KEYWORD: NEW JERSEY                                                
    INDUSTRY KEYWORD: PHARMACEUTICAL                                  
                                                                        
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or
         800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473
-- 



More information about the Virology mailing list

Send comments to us at biosci-help [At] net.bio.net